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Background and Aims: Renal osteodystrophy is common in advanced chronic kidney 
disease (CKD) patients and is characterized by abnormal bone turnover and 
mineralization. Parathyroid hormone (PTH) increases bone turnover through osteoblast 
and osteoclast activation. Osteoprotegerin (OPG) is a decoy receptor of receptor activator 
of nuclear factor kappa-β ligand and thus, inhibits osteoclast maturation. Meanwhile, 
sclerostin is an inhibitor of the Wnt signalling pathway and thus, inhibits osteoblast 
maturation. We aimed to assess the relationship between these bone regulatory markers 




Method: We recruited 43 CKD patients with eGFR<30ml/min/1.73m2 or on dialysis. 
Fasting serum samples were analysed using Immunodiagnostic Systems automated assays 
(Boldon, UK) for intact PTH (iPTH) and BTMs such as bone alkaline phosphatase (bALP) 
and intact procollagen type 1 N-terminal propeptide (intact PINP) which are bone 
formation markers, and tartrate-resistant acid phosphatase 5b (TRAP5b) which is a bone 
resorption marker. OPG and sclerostin were analysed using manual ELISA by Biomedica 
(Vienna, Austria). Trans-iliac bone biopsy was performed after tetracycline labelling. Bone 
samples were analysed using quantitative histomorphometry. Normal bone turnover was 
defined as bone formation rate/bone surface (BFR/BS) of 18 - 38µm3/µm2/year. Spearman 
rank correlation was used to test the relationship between the variables. 
 
 
Results: Median BFR/BS was 32.12 (IQR 17.76 – 48.25) um3/um2/year. 26% of patients 
had low and 40% had high bone turnover. iPTH and OPG were positively correlated with 
BFR/BS (rho = 0.42, p<0.01 and rho = 0.36, p<0.05 respectively). Sclerostin was not 
correlated with BFR/BS. Furthermore, sclerostin did not correlate with bALP and intact 
PINP whereas OPG correlated with TRAP5b (rho = 0.43, p<0.01). iPTH correlated with 
bALP (rho = 0.62, p<0.001), intact PINP (rho = 0.62, p<0.001) and TRAP5b (rho = 0.50, 
p = 0.001). 
 
 
Conclusion: Circulating levels of iPTH and OPG were modestly associated with bone 
turnover but sclerostin was not. There are likely to be bone regulators other than iPTH, 
OPG and sclerostin which regulate bone turnover in renal osteodystrophy. 
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